Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus nab-paclitaxel as second-line treatment for advanced gastric cancer
ChiCTR1900027413Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Objective response rate. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
Rivoceranibpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900027413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027413.